Search Tag: intermittent β-lactam antibiotics

2024 23 Jun

  A new study aimed to determine if continuous infusion of a β-lactam antibiotic (piperacillin-tazobactam or meropenem) reduces all-cause mortality at 90 days compared to intermittent infusion in critically ill patients with sepsis.   The BLING III randomised clinical trial was conducted across 104 ICUs in Australia, Belgium, France, Malaysia,...Read more